Evidence map›Paper›PMID 28348450›Full record

ArticleDisease markers2017

A Novel Panel of Serum Biomarkers for MPM Diagnosis.

A Bonotti, R Foddis, S Landi, O Melaiu, C De Santi, L Giusti, E Donadio, F Ciregia, M R Mazzoni, A Lucacchini and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Disease markers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2021
    Pooled it
  3. Article
  4. Review
  5. Article
  6. The National Cancer Institute Early Detection Research Network: Two Decades of Progress.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020
    Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

A BonottiOperative Unit of Occupational and Environmental Medicine, University Hospital of Pisa, Pisa, Italy.ORCID 0000-0003-4186-0835
R FoddisDepartment of Translational Research and of New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
S LandiDepartment of Biology, University of Pisa, Pisa, Italy.
O MelaiuDepartment of Biology, University of Pisa, Pisa, Italy.
C De SantiDepartment of Biology, University of Pisa, Pisa, Italy.
L GiustiDepartment of Pharmacy, University of Pisa, Pisa, Italy.
E DonadioDepartment of Pharmacy, University of Pisa, Pisa, Italy.
F CiregiaDepartment of Pharmacy, University of Pisa, Pisa, Italy.
M R MazzoniDepartment of Pharmacy, University of Pisa, Pisa, Italy.
A LucacchiniDepartment of Pharmacy, University of Pisa, Pisa, Italy.
M BovenziDepartment of Medical Sciences, University of Trieste, Trieste, Italy.
M ComarDepartment of Medical Sciences, University of Trieste, Trieste, Italy.
E PantaniOperative Unit of Occupational and Environmental Medicine, University Hospital of Pisa, Pisa, Italy.
A PistelliOperative Unit of Occupational and Environmental Medicine, University Hospital of Pisa, Pisa, Italy.
A CristaudoOperative Unit of Occupational and Environmental Medicine, University Hospital of Pisa, Pisa, Italy; Department of Translational Research and of New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
University of Pisa · ITAzienda Ospedaliera Universitaria Pisana · ITUniversity of Trieste · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exposure to asbestos is the main cause of malignant pleural mesothelioma (MPM), a highly aggressive cancer of the pleura. Since the only tools for early detection are based on radiological tests, some authors focused on serum markers (i.e., mesothelin). The aim of this study was the evaluation of new serum biomarkers to be used individually or in combination, in order to improve the outcome of patients whose disease would be diagnosed at an earlier stage. Serum and plasma were available from 43 subjects previously exposed to asbestos and 27 MPM patients, all being epithelioid type. All the new markers found differentially expressed in MPM and healthy subjects, by proteomic and genomic approaches, have been validated in the serum by the use of specific ELISA. The combined approach, using tools of genomics and proteomics, is found to be highly innovative for this type of disease and led to the identification of new serum markers in the diagnosis of MPM. These results, if confirmed in a larger series, may have a strong impact in this area, because early detection of this cancer in people at high risk could significantly improve the course of the disease and the clinical approach to an individualized therapy.

Indexed as

AgedBiomarkers, TumorBlood ProteinsCase-Control StudiesFemaleHumansLung NeoplasmsMaleMesotheliomaMesothelioma, MalignantMiddle AgedProteomeBiomarkers, TumorBlood ProteinsProteome

Identifiers

PMID28348450
PMCPMC5350384
OpenAlexW2593037895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.